Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Int J Cancer ; 125(7): 1626-39, 2009 Oct 01.
Artigo em Inglês | MEDLINE | ID: mdl-19569244

RESUMO

Most malignant features of cancer cells are triggered by activated oncogenes and the loss of tumor suppressors due to mutation or epigenetic inactivation. It is still unclear, to what extend the escape of emerging cancer cells from recognition and elimination by the immune system is determined by similar mechanisms. We compared the transcriptomes of HCT116 colorectal cancer cells deficient in DNA methyltransferases (DNMTs) and of cells, in which the RAS pathway as the major growth-promoting signaling system is blocked by inhibition of MAPK. We identified the MHC Class I genes HLA-A1/A2 and the ULBP2 gene encoding 1 of the 8 known ligands of the activating NK receptor NKG2D among a cluster of immune genes up-regulated under the conditions of both DNMT-deficiency and MEK-inhibition. Bisulphite sequencing analyses of HCT116 with DNMT deficiency or after MEK-inhibition showed that de-methylation of the ULPB2 promoter correlated with its enhanced surface expression. The HLA-A promoters were not methylated indicating that components of the HLA assembly machinery were also suppressed in DNMT-deficient and MEK-inhibited cells. Increased HLA-A2 surface expression was correlated with enhanced recognition and lysis by A2-specific CTL. On the contrary, elevated ULBP2 expression was not reflected by enhanced recognition and lysis by NK cells. Cosuppression of HLA Class I and NKG2D ligands and genes encoding peptide transporters or proteasomal genes mediates a strong functional link between RAS activation, DNMT activity and disruption of the antigen presenting system controlling immune recognition in colorectal cancer cells.


Assuntos
Antineoplásicos/farmacologia , Neoplasias do Colo/imunologia , DNA (Citosina-5-)-Metiltransferases/metabolismo , Antígeno HLA-A2/metabolismo , Peptídeos e Proteínas de Sinalização Intercelular/metabolismo , Quinases de Proteína Quinase Ativadas por Mitógeno/metabolismo , Mutação , Proteínas Proto-Oncogênicas/metabolismo , Proteínas ras/metabolismo , Benzenossulfonatos/farmacologia , Butadienos/farmacologia , Neoplasias do Colo/genética , DNA (Citosina-5-)-Metiltransferase 1 , Regulação para Baixo , Inibidores Enzimáticos/farmacologia , Proteínas Ligadas por GPI , Regulação Neoplásica da Expressão Gênica , Células HCT116 , Humanos , Células Matadoras Naturais/imunologia , Niacinamida/análogos & derivados , Nitrilas/farmacologia , Compostos de Fenilureia , Inibidores de Proteínas Quinases/farmacologia , Proteínas Proto-Oncogênicas p21(ras) , Piridinas/farmacologia , Sorafenibe , DNA Metiltransferase 3B
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...